Immunotherapy for prostate cancer

Lessons from responses to tumor-associated antigens

Harm Westdorp, Annette E. Sköld, Berit A. Snijer, Sebastian Franik, Sasja F. Mulder, Pierre P. Major, Ronan Foley, Winald R. Gerritsen, I. Jolanda M de Vries

Research output: Contribution to journalArticle

Abstract

Prostate cancer (PCa) is the most common cancer in men and the second most common cause of cancer-related death in men. In recent years, novel therapeutic options for PCa have been developed and studied extensively in clinical trials. Sipuleucel-T is the first cell-based immunotherapeutic vaccine for treatment of cancer. This vaccine consists of autologous mononuclear cells stimulated and loaded with an immunostimulatory fusion protein containing the prostate tumor antigen prostate acid posphatase. The choice of antigen might be key for the efficiency of cell-based immunotherapy. Depending on the treatment strategy, target antigens should be immunogenic, abundantly expressed by tumor cells, and preferably functionally important for the tumor to prevent loss of antigen expression. Autoimmune responses have been reported against several antigens expressed in the prostate, indicating that PCa is a suitable target for immunotherapy. In this review, we will discuss PCa antigens that exhibit immunogenic features and/or have been targeted in immunotherapeutic settings with promising results, and we highlight the hurdles and opportunities for cancer immunotherapy.

Original languageEnglish (US)
Article number191
JournalFrontiers in Immunology
Volume5
Issue numberMAY
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Neoplasm Antigens
Immunotherapy
Prostatic Neoplasms
Antigens
Prostate
Neoplasms
Cancer Vaccines
Autoimmunity
Therapeutics
Vaccines
Clinical Trials
Acids
Proteins

Keywords

  • CRPC
  • Immunotherapy
  • Immunotherapy of cancer
  • Prostate cancer
  • Tumor-associated antigens

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Westdorp, H., Sköld, A. E., Snijer, B. A., Franik, S., Mulder, S. F., Major, P. P., ... de Vries, I. J. M. (2014). Immunotherapy for prostate cancer: Lessons from responses to tumor-associated antigens. Frontiers in Immunology, 5(MAY), [191]. https://doi.org/10.3389/fimmu.2014.00191

Immunotherapy for prostate cancer : Lessons from responses to tumor-associated antigens. / Westdorp, Harm; Sköld, Annette E.; Snijer, Berit A.; Franik, Sebastian; Mulder, Sasja F.; Major, Pierre P.; Foley, Ronan; Gerritsen, Winald R.; de Vries, I. Jolanda M.

In: Frontiers in Immunology, Vol. 5, No. MAY, 191, 2014.

Research output: Contribution to journalArticle

Westdorp, H, Sköld, AE, Snijer, BA, Franik, S, Mulder, SF, Major, PP, Foley, R, Gerritsen, WR & de Vries, IJM 2014, 'Immunotherapy for prostate cancer: Lessons from responses to tumor-associated antigens', Frontiers in Immunology, vol. 5, no. MAY, 191. https://doi.org/10.3389/fimmu.2014.00191
Westdorp, Harm ; Sköld, Annette E. ; Snijer, Berit A. ; Franik, Sebastian ; Mulder, Sasja F. ; Major, Pierre P. ; Foley, Ronan ; Gerritsen, Winald R. ; de Vries, I. Jolanda M. / Immunotherapy for prostate cancer : Lessons from responses to tumor-associated antigens. In: Frontiers in Immunology. 2014 ; Vol. 5, No. MAY.
@article{dfcb23bce5614f7d87cb7b207e103ee3,
title = "Immunotherapy for prostate cancer: Lessons from responses to tumor-associated antigens",
abstract = "Prostate cancer (PCa) is the most common cancer in men and the second most common cause of cancer-related death in men. In recent years, novel therapeutic options for PCa have been developed and studied extensively in clinical trials. Sipuleucel-T is the first cell-based immunotherapeutic vaccine for treatment of cancer. This vaccine consists of autologous mononuclear cells stimulated and loaded with an immunostimulatory fusion protein containing the prostate tumor antigen prostate acid posphatase. The choice of antigen might be key for the efficiency of cell-based immunotherapy. Depending on the treatment strategy, target antigens should be immunogenic, abundantly expressed by tumor cells, and preferably functionally important for the tumor to prevent loss of antigen expression. Autoimmune responses have been reported against several antigens expressed in the prostate, indicating that PCa is a suitable target for immunotherapy. In this review, we will discuss PCa antigens that exhibit immunogenic features and/or have been targeted in immunotherapeutic settings with promising results, and we highlight the hurdles and opportunities for cancer immunotherapy.",
keywords = "CRPC, Immunotherapy, Immunotherapy of cancer, Prostate cancer, Tumor-associated antigens",
author = "Harm Westdorp and Sk{\"o}ld, {Annette E.} and Snijer, {Berit A.} and Sebastian Franik and Mulder, {Sasja F.} and Major, {Pierre P.} and Ronan Foley and Gerritsen, {Winald R.} and {de Vries}, {I. Jolanda M}",
year = "2014",
doi = "10.3389/fimmu.2014.00191",
language = "English (US)",
volume = "5",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "MAY",

}

TY - JOUR

T1 - Immunotherapy for prostate cancer

T2 - Lessons from responses to tumor-associated antigens

AU - Westdorp, Harm

AU - Sköld, Annette E.

AU - Snijer, Berit A.

AU - Franik, Sebastian

AU - Mulder, Sasja F.

AU - Major, Pierre P.

AU - Foley, Ronan

AU - Gerritsen, Winald R.

AU - de Vries, I. Jolanda M

PY - 2014

Y1 - 2014

N2 - Prostate cancer (PCa) is the most common cancer in men and the second most common cause of cancer-related death in men. In recent years, novel therapeutic options for PCa have been developed and studied extensively in clinical trials. Sipuleucel-T is the first cell-based immunotherapeutic vaccine for treatment of cancer. This vaccine consists of autologous mononuclear cells stimulated and loaded with an immunostimulatory fusion protein containing the prostate tumor antigen prostate acid posphatase. The choice of antigen might be key for the efficiency of cell-based immunotherapy. Depending on the treatment strategy, target antigens should be immunogenic, abundantly expressed by tumor cells, and preferably functionally important for the tumor to prevent loss of antigen expression. Autoimmune responses have been reported against several antigens expressed in the prostate, indicating that PCa is a suitable target for immunotherapy. In this review, we will discuss PCa antigens that exhibit immunogenic features and/or have been targeted in immunotherapeutic settings with promising results, and we highlight the hurdles and opportunities for cancer immunotherapy.

AB - Prostate cancer (PCa) is the most common cancer in men and the second most common cause of cancer-related death in men. In recent years, novel therapeutic options for PCa have been developed and studied extensively in clinical trials. Sipuleucel-T is the first cell-based immunotherapeutic vaccine for treatment of cancer. This vaccine consists of autologous mononuclear cells stimulated and loaded with an immunostimulatory fusion protein containing the prostate tumor antigen prostate acid posphatase. The choice of antigen might be key for the efficiency of cell-based immunotherapy. Depending on the treatment strategy, target antigens should be immunogenic, abundantly expressed by tumor cells, and preferably functionally important for the tumor to prevent loss of antigen expression. Autoimmune responses have been reported against several antigens expressed in the prostate, indicating that PCa is a suitable target for immunotherapy. In this review, we will discuss PCa antigens that exhibit immunogenic features and/or have been targeted in immunotherapeutic settings with promising results, and we highlight the hurdles and opportunities for cancer immunotherapy.

KW - CRPC

KW - Immunotherapy

KW - Immunotherapy of cancer

KW - Prostate cancer

KW - Tumor-associated antigens

UR - http://www.scopus.com/inward/record.url?scp=84905439880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905439880&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2014.00191

DO - 10.3389/fimmu.2014.00191

M3 - Article

VL - 5

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - MAY

M1 - 191

ER -